7T MRS in Parkinson's Disease

This study is looking for healthy controls and patients with Parkinson's (PD) to perform an MR scan.

1. The neurochemical profile of the SN of patients with PD as measured by high field MRS will differ from that of healthy controls, in that glutathione will be lower due to oxidative stress, lactate will be higher due to mitochondrial dysfunction, the gliosis markers myo-inositol and glutamine will be higher due to inflammation (glial activation) and N-acetylaspartate and glutamate will be lower due to neuronal loss/damage. 2. There will be a relationship between neurochemical changes and disease severity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson's Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

45 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Minnesota/CMRR

Minneapolis, Minnesota, 55414, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Parkinson's disease Group

Parkinson's disease (clinical diagnostic criteria)
Age 45-75 years inclusive
Able to safely undergo MRI scanning
Absence of diabetes and smoking
Capable of giving informed consent

Healthy Control Group

Age 45-75 years inclusive
Able to safely undergo MRI scanning
Absence of diabetes and smoking
Capable of giving informed consent

Exclusion criteria

Parkinson's disease Group

Dementia (clinically determined by PI Dr. Tuite)
Diagnosis of atypical parkinsonism
Inability to safely undergo MRI scanning
Inability to give informed consent
Unstable medical conditions
Present smoker
Diabetic (on oral or injectable medications for diabetes)
Taken coenzyme Q10 or Vitamin E in the 2 weeks prior to the scan
Does not meet age criteria

Healthy Control Group

Has a 1st degree relative with PD
Dementia (clinically determined by PI Dr. Tuite)
Inability to safely undergo MRI scanning
Inability to give informed consent
Unstable medical conditions
Present smoker
Diabetic (on oral or injectable medications for diabetes)
Taken coenzyme Q10 or Vitamin E in the 2 weeks prior to the scan
Does not meet age criteria

Treatment and study plan

Primary outcomes

Magnetic resonance spectroscopy (MRS)

Time frame: Baseline

We will utilize optimized magnetic resonance spectroscopy (MRS) methodology to address theories of pathogenesis of Parkinson's disease (PD) by quantifying glutathione (GSH), lactate, glutamine and myo-inositol levels of the unilateral substantia nigra (SN) of healthy volunteers and patients with PD.

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Official study title

Magnetic Resonance Spectroscopy of Parkinson's Disease at 7 Tesla

Important dates

Study start: 2010
Primary completion: 2019
Study completion: 2019
First posted: Nov 9, 2010
Registry last updated: Nov 1, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed